EvolveImmune Therapeutics
Xingyue (Amy) An is a Scientist at EvolveImmune Therapeutics since July 2020, with previous experience as a Postdoctoral Researcher and Graduate Research Assistant at the University of Houston from August 2013 to June 2020. During the doctoral studies, Xingyue An focused on single-cell functional profiling of lymphocytes for cancer immunotherapy, under the guidance of Dr. Navin Varadarajan. Key achievements include the optimization of a microfluidics-based platform for single-cell analysis, collaboration with The University of Texas MD Anderson Cancer Center on T cell research, and mentoring undergraduate and graduate researchers. Additionally, experience includes serving as a Graduate Teaching Assistant for various chemical engineering courses. Xingyue An holds a PhD in Chemical Engineering from the University of Houston and a BS in Chemical Engineering from Tianjin University.
EvolveImmune Therapeutics
2 followers
EvolveImmune Therapeutics is a next-generation immunotherapy platform company based in Farmington and Branford, CT. Building upon research that originates from the Sidi Chen Lab at Yale University, EvolveImmune is leveraging a novel in vivo target discovery platform to develop a broad portfolio of first-in-class molecules for unmet needs in oncology and autoimmune diseases.